Publications by authors named "Ash A Alizadeh"

Claim this Profile
R
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
Mark Roschewski, David M Kurtz, Jason R Westin, Ryan C Lynch, Ajay K Gopal, Ash A Alizadeh

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
Steven Wang, Marcel Nijland, Leonie Strobbe, Margriet Oosterveld, Rinske Boersma, Ash A Alizadeh

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic/pharmacodynamic model predicts tumor debulking improves CAR T-cell efficacy in Large B-Cell Lymphoma.
Amy E Pomeroy, Brian J Sworder, Deborah Plana, Yanguang Cao, Ash A Alizadeh

Blood Cancer Discov· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.
Mark P Hamilton, Nick Phillips, Troy Noordenbos, Jan Boegeholz, Takeshi Sugio, Ash A Alizadeh

Res Sq· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Prospective Trial of Pembrolizumab Monotherapy in Metastatic NSCLC Evaluating Circulating Tumor DNA as a Surrogate Biomarker of Response.
Iris van 't Erve, Isabelle Blanchard, Judy Y Pagtama, Alison J Holmes Tisch, Ash A Alizadeh

JTO Clin Res Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma.
Ajay Subramanian, Shengqin Su, Jamie Flerlage, Stefan Alig, Sheren Younes, Ash A Alizadeh

Nat Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.
Everett J Moding, Mohammad Shahrokh Esfahani, Cheng Jin, Angela B Hui, Barzin Y Nabet, Ash A Alizadeh

Cancer Discov· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.
Paolo Strati, Lei Feng, Jason R Westin, Ranjit Nair, Luis E Fayad, Ash A Alizadeh

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine-guided dual-objective protein engineering for deimmunization and therapeutic functions.
Eric Wolfsberg, Jean-Sebastien Paul, Josh Tycko, Binbin Chen, Michael C Bassik, Ash A Alizadeh

Cell Syst· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.
Sravya Tumuluru, James K Godfrey, Alan Cooper, Jovian Yu, Xiufen Chen, Ash A Alizadeh

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy.
Jordan S Goldstein, Nick A Phillips, Ash A Alizadeh

Blood Cancer Discov· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An ultrasensitive method for detection of cell-free RNA.
Monica C Nesselbush, Bogdan A Luca, Young-Jun Jeon, Isabel Jabara, Catherine B Meador, Ash A Alizadeh

Nature· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.
Pablo Domizi, Jolanda Sarno, Astraea Jager, Milton Merchant, Kaithlen Zen B Pacheco, Ash A Alizadeh

Nat Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-Free DNA in Hematologic Malignancies.
Joseph G Schroers-Martin, Ash A Alizadeh

JCO Oncol Pract· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.
Soyeong Jun, Nikhil A Shukla, Greg Durm, Angela B Hui, Sha Cao, Ash A Alizadeh

J Thorac Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.
Mark P Hamilton, Ash A Alizadeh

Transplant Cell Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply.
Mark P Hamilton, David B Miklos, Ash A Alizadeh

N Engl J Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer.
Yonina R Murciano-Goroff, Angela B-Y Hui, Jose A Araujo Filho, Emily G Hamilton, Jacob J Chabon, Ash A Alizadeh

JCO Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Mark P Hamilton, Erin Craig, Cesar Gentille Sanchez, Alain Mina, John Tamaresis, Ash A Alizadeh

Blood Adv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.
Mark P Hamilton, Takeshi Sugio, Troy Noordenbos, Shuyu Shi, Philip L Bulterys, Ash A Alizadeh

N Engl J Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
ViPOR's Venom - Rationally Targeting DLBCL with Precision.
Jordan S Goldstein, Ash A Alizadeh

N Engl J Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis.
Tej D Azad, Shigeki Nanjo, Michael C Jin, Jacob J Chabon, David M Kurtz, Ash A Alizadeh

NPJ Precis Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma.
Sravya Tumuluru, James K Godfrey, Alan Cooper, Jovian Yu, Xiufen Chen, Ash A Alizadeh

bioRxiv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.
Jenna M Kastenschmidt, Joseph G Schroers-Martin, Brian J Sworder, Suhas Sureshchandra, Michael S Khodadoust, Ash A Alizadeh

Cell Stem Cell· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas.
Navika D Shukla, Joseph G Schroers-Martin, Brian J Sworder, Karan Raj Kathuria, Stefan K Alig, Ash A Alizadeh

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis